Advisory for DermaVir – Can it change the treatment paradigm of HIV? This is the question this privately held clinical-stage biotechnology company is focusing on by developing and commercialising a revolutionary new immunotherapy technology platform for the treatment of chronic viral infections, cancer and allergy. Their Platform Technology includes an antigen specific plasmid DNA (pDNA) that is encapsulated in a nanomedicine formulation to make it closely resemble a virus, and a topical (through the skin) administration device. Their Lead Therapeutic Vaccine for treatment of HIV, referred to as ”Derma Vir” is effective in boosting immune response which in turn kills HIV-infected cells. See DermaVir.